Introduction
============

The upper respiratory tract is simultaneously exposed to a vast range of potential pathogenic bacteria and viruses. A well-recognized viral--bacterial coinfection in the lung is the synergy between influenza virus and *Streptococcus pneumoniae* (SP; or pneumococcus).[@b1-copd-12-1973]--[@b5-copd-12-1973] Influenza can suppress the immune response to SP infection and also result in upregulation of pneumococcal adhesion molecules, leading to increased pneumococcal load and decreased survival.[@b1-copd-12-1973],[@b2-copd-12-1973],[@b5-copd-12-1973],[@b6-copd-12-1973] Therefore, secondary pneumococcal pneumonia might lead to an increase in respiratory morbidity and mortality (predominantly due to chronic obstructive pulmonary disease \[COPD\]) associated with influenza infections.[@b5-copd-12-1973],[@b7-copd-12-1973]

McCullers[@b1-copd-12-1973] indicated that although an influenza infection alone can be severe, mortality increases significantly when a bacterial superinfection occurs, as in the 1918 influenza pandemic, when millions of people died, mostly from secondary pneumococcal pneumonia. Chertow and Memoli[@b5-copd-12-1973] indicated the clinical course and microbiology of severe influenza and bacterial coinfection. The bacterial coinfection commonly occurs within the first 6 days of influenza infection and presents similarly to influenza infection occurring alone, but with an increased risk of death.[@b5-copd-12-1973] Chertow and Memoli[@b5-copd-12-1973] further indicated that bacterial coinfection complicated up to 34% of 2009 pandemic influenza A virus (IAV; H1N1) infections managed in intensive care units worldwide. Globally, more than 3.1 million deaths attributable to influenza and pneumonia occur annually.[@b8-copd-12-1973] Therefore, it is critical to quantify and understand the risk of influenza and SP coinfection and initiate potentially effective control measures and treatment strategies, as well as clinical care.

Several mechanisms have been proposed to explain the synergistic interactions observed in virus--bacteria coinfection. Influenza has been shown to increase bacterial adherence or proliferation by disruption of the epithelial barrier, production of viral neuraminidase,[@b4-copd-12-1973] and reduction in the efficiency of the immune system, such as induced neutrophil apoptosis and dysfunction,[@b9-copd-12-1973] as well as depressed phagocytic activity in macrophages through the expression of different cytokines (eg, IFNα/*β*,[@b10-copd-12-1973] IFNγ,[@b11-copd-12-1973] TNFα,[@b12-copd-12-1973] and IL10[@b13-copd-12-1973]). On the other hand, the presence of bacteria might facilitate subsequent viral infection by secreting proteases that activate the infectivity of influenza[@b14-copd-12-1973] and producing bacterial neuraminidase to enhance the release of virions.[@b15-copd-12-1973]

Shrestha et al[@b16-copd-12-1973] developed mathematical within-host or transmission-dynamic models to characterize the nature, timing, and magnitude of coinfection interaction. In particular, they developed an "SIRS" compartmental model with influenza incidences incorporated for characterizing pneumococcal transmission where S, I, and R represent susceptible, infectious, and recovered individuals, respectively. They indicated a short-lived but strong interaction (\~100-fold) of increased susceptibility to pneumococcal pneumonia postinfluenza infection. Meanwhile, they derived an immunomediated model quantifying virus--bacteria interaction and proposed advice on clinical management that antiviral treatment should be administered no later than 4 days after influenza infection.[@b17-copd-12-1973] In addition, Smith et al[@b15-copd-12-1973],[@b18-copd-12-1973] established a virus--bacteria--host kinetic model to investigate interaction during coinfection based on various bacterial inoculum sizes (100 CFU versus 1,000 CFU D39) and virus strains (PR8 versus PR8-PB1-F2\[1918\]).

Collectively, based on the aforementioned synergistic mechanisms, well-established mathematical within-host dynamic models, and review articles regarding in vivo experiments,[@b1-copd-12-1973],[@b4-copd-12-1973] the modeling of secondary SP coinfection from influenza reveals three key ways where coinfection can affect transmission and disease: 1) each infection alters the ability of the immune system to mount an adequate immune response to the other infection, 2) morbidity and mortality of coinfection can be independent of pathogen burden or excessive inflammatory response, and 3) symptoms and effects of secondary pathogen coinfection may be exacerbated compared to primary pathogen infection. Therefore, understanding how coinfection affects the dynamics and control of important infectious diseases has become increasingly significant. Although changes in the course of infection of coinfected individuals have been observed, the mechanisms of how transmission is altered are poorly understood.

In this study, our modeling framework is based on the mathematical within-host dynamics of coinfection with IAV and SP developed in Smith et al.[@b15-copd-12-1973] When and what causes the increased pneumonia-exacerbation risk from SP coinfection in influenza infection, however, is not well quantified or assessed. Therefore, explicitly modeling the interaction between influenza and SP is important for understanding how coinfection may impact the incidence, copathogenesis, and efficacy of clinical management, which relies on measures to prevent, diagnose, and treat both influenza and bacterial infection. The purpose of this study is threefold: 1) to provide an integrated probabilistic risk-assessment framework to quantify exacerbated risks in inflammatory responses for secondary pneumococcal pneumonia patients coinfected with influenza, 2) to investigate coinfection interactions between influenza and SP through identifying variations in cytokine level reflecting severity in inflammatory response of three biomarkers, and 3) to conduct the risk assessment for patients with COPD who develop the coinfection of influenza and pneumonia.

Materials and methods
=====================

Study framework
---------------

The study framework for quantifying IAV and SP coinfection-associated inflammation exacerbation-risk assessment is demonstrated in [Figure 1](#f1-copd-12-1973){ref-type="fig"}. Briefly, we started with searching previously published mouse experimental studies related to IAV and SP coinfection and epidemiological studies regarding IAV infection-associated pneumonia to understand the potential health risks of IAV-SP coinfection ([Figure 1A](#f1-copd-12-1973){ref-type="fig"}). This study then implemented a mathematical within-host coinfection dynamic model to quantify virus dynamically, as well as bacterial burden in mice ([Figure 1B](#f1-copd-12-1973){ref-type="fig"}). Parameterization and uncertainty analysis of a coinfection dynamic model is carried out as well ([Figure 1C](#f1-copd-12-1973){ref-type="fig"}). Dose--response relationships between transferred bacterial loads and normalized inflammatory effects can then be established for further implementation and implications for pneumonia and COPD-risk assessment ([Figure 1D--F](#f1-copd-12-1973){ref-type="fig"}).

Study data
----------

There were sporadic human epidemiological data relating to IAV-SP coinfection. Therefore, we principally collated IAV-SP coinfection experimental data based on mouse models from previously published studies. [Table S1](#SD2-copd-12-1973){ref-type="supplementary-material"} summarizes the data extracted from published mouse-coinfection literature covering ages and species (such as C57BL/6 and BALB/c mice), as well as inoculated strains and doses of virus and bacteria. Moreover, data in [Table S1](#SD2-copd-12-1973){ref-type="supplementary-material"} also indicate explicitly the infection in emphysematous lung. We then extrapolated bacterial loads and corresponding cytokine levels in mice to those in humans with caution.

Based on a previously published in vivo coinfection assay, mice were infected intranasally with IAV on day 0 with doses of 1.4--1.8×10^5^ 50% tissue culture infective dose (TCID~50~)⋅mL^−1^ and then challenged with SP of 10^2^--10^7^ CFU⋅mL^−1^ at 3--14 days post-IAV infection. Following virus and bacterial inoculation, mice were anesthetized and killed at 12--72 hours post-IAV infection, and cytokine levels of IL6, IL10, keratinocyte chemoattractant (KC), TNFα, and IFNγ in supernatants extracted from lung homogenates were quantified by either enzyme-linked immunosorbent assay or such instruments as Luminex readers.

To select representative cytokines for studying bacterial load-dependent inflammation, we established preliminary linear models. As we aimed at constructing best-fit linear models, some data points potentially presenting as outliers relative to linear models were excluded; therefore, only a few studies were explored (see [Figure S1](#SD1-copd-12-1973){ref-type="supplementary-material"} and [Table S1](#SD2-copd-12-1973){ref-type="supplementary-material"}). Additionally, both criteria, including coefficient of determination (*r*^2^\>0.8) and *P*-value (*P*\<0.05), were adopted simultaneously to select representative cytokines, ie, IL6, TNFα, and IFNγ ([Figure S1](#SD1-copd-12-1973){ref-type="supplementary-material"}).

On the other hand, epidemiological data of IAV infection-associated pneumonia (Pna) patients were selected carefully for determining the severity of inflammatory effects ([Table S2](#SD3-copd-12-1973){ref-type="supplementary-material"}). Briefly, nasopharyngeal swab samples were collected from hospitalized patients for RNA isolation using a viral RNA minikit.[@b19-copd-12-1973] Moreover, inflammatory cytokine levels were measured from serum samples collected from all Pna patients. Note that we chose three representative inflammatory cytokines existing in mice and humans -- IFNγ, TNFα, and IL6 -- for quantifying inflammatory effects.

Coinfection transmission-dynamic modeling
-----------------------------------------

A previously well-developed IAV-SP coinfection model[@b15-copd-12-1973] capturing three population phases -- epithelial cells, virus (*V*), and bacteria (*B*) -- was adopted to explore the contribution of secondary infection with SP to the interaction dynamics between influenza and pneumococcus ([Figure 1B](#f1-copd-12-1973){ref-type="fig"}). Briefly, uninfected epithelial cells (*T*) would become virus-productive infected cells (*J*) by influenza virus (*V*) after 6--8 hours latency of unproductive infected cells (*I*). The consequences of coinfection can be quantified by four major mechanisms of virus--bacteria--immune system interactions ([Figure 1B](#f1-copd-12-1973){ref-type="fig"}): 1) the viral infection can enhance bacterial adherence to epithelial cells, resulting in elevated bacteria-carrying capacity; 2) the carrying capacity can weaken the ability of alveolar macrophages to phagocytize bacteria; 3) with the presence of bacteria, which can synergistically promote virion release; and 4) released virions can increase epithelial cell death from bacterial adherence. The details of model equations describing the dynamics of IAV inoculation and transmission, IAV transmission postcoinfection with SP, and SP transmission given coinfection are given in [Table 1](#t1-copd-12-1973){ref-type="table"}. The simulation of IAV-SP coinfection-transmission dynamics was performed with Berkeley Madonna (version 8.0.1; University of California at Berkeley, Berkeley, CA, USA).

To assess the performance of model predictability (ie, model validation) for mice coinfected with IAV and SP, the mean absolute percentage error (MAPE) was calculated as $\text{MAPE} = 1/N{\sum_{n = 1}^{N}{\left| {C_{o,n} - C_{m,n}} \right|/C_{o,n} \times 100\%}}$ where *N* denotes the number of observations, *C~o,n~* the observed experimental data, and *C~m,n~* the modeled result corresponding to data point *n*.

Dose--response analysis
-----------------------

To extrapolate the mouse doses, including bacteria load (*D*~M~) and inflammatory cytokine level (*CL*~M~), to human doses (*D*~H~ and *CL*~H~) due to coinfection with IAV and SP, we applied the concept of human equivalent dose (HED) to transfer doses of mice into those of humans.[@b20-copd-12-1973] Here, *D*~H~ or *CL*~H~ can be calculated accordingly as $$\left( {D_{H},CL_{H}} \right) = \left( {D_{M},CL_{M}} \right) \times \frac{K_{M}}{K_{H}}$$where *K*~M~ and *K*~H~ are the body-surface area-related transfer factors for mice and humans, respectively, of 3 and 37⋅kg m^−2^.[@b20-copd-12-1973]

Due to lack of information regarding the combinative impact of coinfection with IAV and SP on human inflammatory responses, we thus normalized Pna-associated inflammatory effect (*IE*) to capture the level of response in Pna patients potentially coinfected with IAV followed by SP as $$IE = \frac{CL_{H} - CL_{\text{Pna},2.5}}{CL_{\text{Pna},2.5}}$$where *CL*~H~ is the level of inflammatory cytokines in humans extrapolated from mice and *CL*~Pna,2.5~ the percentile 2.5 of inflammatory cytokine levels (eg, IL6, TNFα, and IFNγ) estimated from patients with influenza-associated Pna as the baseline values representing coinfection, since there is no such information for cytokine values within coinfected Pna patients.

Dose--response relationships between *D*~H~ and *IE* can then be constructed by fitting those estimated values with the most suitable equations, resulting in a conditional probability of *IE* given all probable *D*~H~ taken into account (ie, *P*\[*IE*\|*D*~H~\]). TableCurve 2D (version 5.01; AISN Software, Mapleton, OR, USA) was used to fit the published epidemiological data to determine the governing dose--response relationships.

Probabilistic risk assessment
-----------------------------

Bacteria load in mouse lungs estimated from the IAV-SP coinfection dynamic-transmission model can be further transformed into bacteria load in human lungs (*D*~H~). Taking potential factors (eg, certain immune responses, underlying coinfection mechanisms, and different days of SP inoculation post-IAV infection) influencing coinfection dynamics into consideration would obtain a probability density function (ie, the prior probability (*P*\[*D*~H~\])). We then linked *P*(*D*~H~) with *P*(*IE*\|*D*~H~) by Bayesian inference to construct inflammatory risk profiles related to coinfection-induced Pna, resulting in a joint probability function (ie, posterior probability) that can be expressed mathematically as $$P\left( {R_{\text{CoI}}\left( {IE} \right)} \right) = P\left( D_{H} \right) \times P\left( IE \middle| D_{H} \right)$$

To better understand the likely excess exacerbations risks of coinfection, we used the maximum probability of 1 to subtract the cumulative risk profile, ie, 1− *P*(*R*~CoI~(*IE*)), leaving an exceedance-risk profile, indicating that there is a certain probability for inflammatory responses to exceed such a level. Moreover, to quantify extents of coinfection-exacerbated inflammation, this study defined a tertiary inflammatory response as mild (I), moderate (II), and severe (III) according to lower- and upper-tertile estimates (33rd and 67th) in probability density functions for cytokine levels of IL6, TNFα, and IFNγ from influenza-infected Pna patients. The 33rd- and 67th-percentile estimates of cytokine levels can then be transformed into inflammation folds to represent classes in inflammatory response based on our normalization methodology described.

Uncertainty and sensitivity analysis
------------------------------------

A Monte Carlo (MC) simulation technique was implemented to generate percentiles 2.5 and 97.5 as 95% CIs for quantifying the uncertainty of parameters and inoculation day-varied bacteria loads based on the IAV-SP coinfection dynamic model. Kolmogorov--Smirnov goodness-of-fit statistics were used to determine the optimal distributions for parameters and bacteria loads.

We also applied the MC simulation to quantify the uncertainty and its impact on the estimations of expected inflammatory risks. The MC simulation was performed with 10,000 iterations to ensure the stability of results. Crystal Ball software (version 2000.2; Decisioneering, Denver, CO, USA) was employed to implement the MC simulation. Moreover, this study employed a one-way sensitivity analysis to assess the contribution of change in each parameter used in the IAV-SP coinfection dynamic model at one time across its 95% CI to the simulation outcome.

Results
=======

IAV-SP coinfection dynamics
---------------------------

We incorporated *V*(0) =2 TCID~50~⋅mL^−1^, *B*(0) =100 CFU⋅mL^−1^ at day 7 coinfection and the essential input-parameter values ([Table 2](#t2-copd-12-1973){ref-type="table"}) derived from Smith et al into the IAV-SP coinfection model[@b15-copd-12-1973] to capture the interaction dynamics among epithelial cells, virus, and bacteria ([Figure 2](#f2-copd-12-1973){ref-type="fig"}). Our results showed that unproductive infected cells (*I*) and virus-productive infected cells (*J*) increased significantly and peaked approximately at day 3 after IAV infection ([Figure 2A](#f2-copd-12-1973){ref-type="fig"}). Meanwhile, peak activity was observed in virus with 6.7 log TCID~50~⋅mL^−1^ ([Figure 2B](#f2-copd-12-1973){ref-type="fig"}). By contrast, as the peak of virus titer approached, uninfected epithelial cells (*T*) decreased dramatically by virtue of virion infection ([Figure 2A](#f2-copd-12-1973){ref-type="fig"}).

After day 7, while bacterial inoculation was occurring, a second virus titer peak was observed around day 8, with a slightly lower concentration of 6.2 log TCID~50~⋅mL^−1^ compared to the first peak ([Figure 2B](#f2-copd-12-1973){ref-type="fig"}). We also found that bacteria load increased rapidly and reached the maximum value of 8.4 log CFU⋅mL^−1^, even though viral titers decreased continuously. Comparisons between predictions by the IAV-SP coinfection model and observed experimental data are demonstrated in [Figure 2B](#f2-copd-12-1973){ref-type="fig"}, indicating that predictions were in apparent agreement with data derived from Smith et al[@b15-copd-12-1973] for virus titer (MAPE 31.64%) and bacteria load (MAPE 14.19%), respectively.

Inflammatory effects on postcoinfection
---------------------------------------

[Table 3](#t3-copd-12-1973){ref-type="table"} lists bacteria loads and inflammatory cytokine levels of IL6, TNFα, and IFNγ of mice and humans (extrapolated based on [Tables S1](#SD2-copd-12-1973){ref-type="supplementary-material"} and [S2](#SD3-copd-12-1973){ref-type="supplementary-material"}), as well as the inflammatory responses obtained by normalizing with percentile-2.5 estimates of cytokine levels (*CL*~Pna,2.5~) detected from IAV- infection Pna patients. Here, *CL*~Pna,2.5~ estimates of IL6, TNFα, and IFNγ were 5.67, 0.41, and 0.23 pg⋅mL^−1^, respectively. The estimated bacteria loads in human (*D*~H~s) were highest for IL6 at 6.12±0.99, followed by TNFα at 5.74±1.44 and IFNγ at 5.71±2.73 log CFU⋅mL^−1^. On the other hand, the extrapolated cytokine levels (*CL*~H~s) for IL6, TNFα, and IFNγ were, respectively, estimated to be 2.88±0.28, 2.74±0.4, and 1.51±0.47 log pg⋅mL^−1^ ([Figure 3](#f3-copd-12-1973){ref-type="fig"}, [Table 3](#t3-copd-12-1973){ref-type="table"}).

Our results revealed that the simple linear equations were found to be adequate for capturing the relationships between log-transferred *D*~H~ and *IE* for IAV infection Pna patients. Specifically, the simple linear equation fitted well with the *D*~H~--*IE* relationships of TNFα (*IE* =477*D*~H~ −1,079, *r*^2^=0.91; *P*\<0.001) ([Figure 3B](#f3-copd-12-1973){ref-type="fig"}) and IL6 (*IE* =80*D*~H~ −335, *r*^2^=0.81; *P*\<0.01) ([Figure 3A](#f3-copd-12-1973){ref-type="fig"}) compared to the relationship of IFNγ (*IE* =48*D*~H~ −87, *r*^2^=0.83; *P*=0.09) ([Figure 3C](#f3-copd-12-1973){ref-type="fig"}). We thus found that human bacteria loads in lungs were positively correlated with inflammatory responses. We also observed that given the same level increases in *D*~H~, TNFα displayed the significantly severer inflammatory responses compared to IL6 and IFNγ, indicating that it was likely to be the most sensitive biomarker for coinfection-exacerbated inflammation among the three cytokines explored in this study.

Pneumonia exacerbation-risk estimates
-------------------------------------

Results of sensitivity analyses demonstrated that changes in each coinfection parameter across its median and 95% CI contributed approximately the same to the mouse-coinfection dynamics at day 7 postcoinfection, resulting in an average bacteria load of 1.78×10^8^ CFU⋅mL^−1^ with 95% CI of 1.02--36.35×10^7^ CFU⋅mL^−1^ ([Figure 4](#f4-copd-12-1973){ref-type="fig"}). On the other hand, changes in different levels of IAV and SP inoculation did not impact much on bacteria load, given the same day of SP inoculation post-IAV infection considered, except for initial virus titer (*V*~0~) of 0.35 TCID~50~⋅mL^−1^ and initial bacteria load (*B*~0~) of 10^2^ CFU⋅mL^−1^ with SP inoculating at days 1 and 9, respectively ([Figure 5A and B](#f5-copd-12-1973){ref-type="fig"}). Moreover, we recognized that days of secondary SP inoculation (ie, days 1, 7, and 9) impacted more on coinfection than that by considering various initial IAV (0.35--1.45 TCID~50~⋅mL^−1^) and SP doses (10^2^ --10^5^ CFU⋅mL^−1^) ([Figure 5C](#f5-copd-12-1973){ref-type="fig"}). We also found SP inoculation at day 7 post-IAV infection would lead to the highest bacteria loads of 21.98±4.42×10^7^ CFU⋅mL^−1^ (ie, susceptibility to SP inoculation) compared to SP inoculation at day 1 or 9 ([Figure 5C](#f5-copd-12-1973){ref-type="fig"}).

This study hence exclusively considered different days of SP coinfection post-IAV infection varied with high, medium, and low initial IAV and SP loads and incorporated them into the coinfection dynamics to better assess the IAV-SP Pna-exacerbation risks. [Figure 6A--C](#f6-copd-12-1973){ref-type="fig"} demonstrates the probability density profiles of *D*~H~, which can be well described by lognormal distributions with estimated geometric means of 3.88 (95% CI 1.26--10.98), 6.25 (95% CI 2.5--14.6), and 4.43 (95% CI 1.6--11.81) log CFU⋅mL^−1^ for days 1, 7, and 9 post-IAV infection. This study thus inferred the worst inflammatory effects would occur with SP introduction at day 7 post-IAV infection, which had 50% risk probability for inflammatory responses of IL6, TNFα, and IFNγ to exceed 166 (95% CI 101--231), 1,899 (95% CI 1,604--2,194), and 215 (95% CI 0--527)-fold, respectively ([Figure 6D--I](#f6-copd-12-1973){ref-type="fig"}, [Table S3](#SD4-copd-12-1973){ref-type="supplementary-material"}).

Furthermore, we classified inflammatory responses of IL6, TNFα, and IFNγ accordingly as I\<101\<II\<414\<III, I\<63\<II\<708\<III, and I\<155\<II\<369\<III, where I, II, and III represent categorized regions of mild, moderate, and severe inflammatory responses, respectively. However, this study found that only while considering the worst Pna-induced inflammatory effects, eg, 20% risk probability (less likely to occur), would there be inflammatory effects of IL6 and IFNγ fall at regions II and III for day 1, 7, and 9 coinfection scenario ([Figure 6G and I](#f6-copd-12-1973){ref-type="fig"}). On the other hand, for TNFα, all scenarios (ie, various risk probabilities) in IAV-SP coinfection (ie, on days 1, 7, and 9 coinfection) would unexceptionally develop moderate and mainly severe inflammatory responses, implying that TNFα was a potentially sensitive indicator for coinfection-exacerbated inflammation among the three cytokines studied ([Figure 6H](#f6-copd-12-1973){ref-type="fig"}).

Discussion
==========

Coinfection mathematical modeling
---------------------------------

Mathematical models have long been recognized as useful tools in exploring complicated relationships with underlying infectious disease-transmission processes.[@b21-copd-12-1973] The accuracy of the predictions obtained from mathematical modeling studies depends on the accuracy of the estimates for parameters governing the model dynamics. Good parameter estimates are needed to better understand and model the potential spread of influenza and SP coinfection.[@b15-copd-12-1973],[@b17-copd-12-1973] Therefore, interpretation of available data from experimental studies provides a platform to link mathematical models, such as infection dynamics, corresponding responses, and efficacy of different control measures for influenza and secondary bacterial coinfection.

Smith et al[@b15-copd-12-1973],[@b18-copd-12-1973] developed a kinetic model that can quantify and describe the mechanisms of influenza coinfection with SP, making it helpful to develop potentially effective therapeutic strategies. It can also help in understanding interactions of copathogenesis between influenza and bacterial pathogens, eg, influenza infection enhances bacterial adherence to epithelial cells, as well as alveolar macrophage dysfunction.[@b1-copd-12-1973],[@b2-copd-12-1973] On the other hand, increased bacterial adherence enhances viral release from infected cells and elevates the death rate of infected cells. Our simulated results of pathogen dynamics were in good agreement with Smith et al,[@b15-copd-12-1973] with MAPE of nearly 30% and 14%, respectively, for influenza titer and bacteria load. To the best of our knowledge, this is the first study estimating simultaneously bacteria loads of SP and quantifying the probable inflammation risks as well as the corresponsive severity regimes of inflammatory responses in influenza-infected Pna patients coinfected with SP at different days (ie, days 1, 7, and 9).

Cytokine-specific inflammatory effects
--------------------------------------

Cytokines can cause both specific and aspecific effects, such as immune damage and viral replication in the lungs. In animal models, cytokines can lead to irreparable tissue destruction as proinflammatory damage in the alveoli.[@b22-copd-12-1973] Proinflammatory cytokines, such as IL6, IFNγ, and TNFα, are required for immunoprotection, yet releasing large proinflammatory cytokines can become toxic. Onishi et al[@b23-copd-12-1973] suggested that rapid bacterial growth may be caused by excess proinflammatory cytokine response due to rapid viral replication in a vulnerable lung environment. On the other hand, the present study has confirmed that the antiviral effects occurred during coinfection with the presence of proinflammatory cytokines. Li et al[@b24-copd-12-1973] suggested that SP infection was linked to high concentration of type I IFN in animal model.

Studies have demonstrated that cytokine induction after infection with proinflammatory stimuli, or even with SP, in vitro and in vivo.[@b13-copd-12-1973],[@b25-copd-12-1973] They suggested that proinflammatory cytokines, such as IFNγ, TNFα, and IL6, were more likely to be key mediators of acute influenza-induced symptoms. One human experimental study has indicated that an intranasal influenza inoculation was followed by increased levels of TNFα and IL6 in nasal lavage fluid.[@b26-copd-12-1973] Similarly, significant induction of cytokines, including TNFα and IL6, was found in human lung tissue, followed by pneumococcal infection. These studies imply that the relationships among bacteria loads/virus titers and cytokine levels could be treated in a dose--response manner for reflecting the severity of symptoms followed by coinfection with influenza and pneumococcus.

Our study constructed a Pna-associated inflammatory risk profile using Bayesian inference to predict the risk of inflammatory response postcoinfection with IAV and SP. Specifically, IL6 and TNFα are well-known mediators on the effects of attraction and activation of inflammatory cells, increased microvascular permeability, bronchoconstriction, bronchial hyperreactivity, and changes in mucus and surfactant production.[@b27-copd-12-1973] On the other hand, IFNγ is a known cytokine critical in innate and adaptive immunity against viral, some bacterial, and protozoal infections.

This study selected five common cytokines (IL6, IL10, KC, TNFα, and IFNγ) initially to characterize coinfection-exacerbated inflammation. Due to limited experimental studies and our aim to construct best-fit linear dose--response relationships, only three cytokines (IL6, TNFα, and IFNγ) and few studies were adopted in quantifying exacerbated inflammatory responses, though several studies supported our idea to adopt these cytokines.[@b25-copd-12-1973]--[@b29-copd-12-1973] This study further indicated TNFα might be the most sensitive biomarker and set as an early warning signal among the three explored cytokines for reflecting inflammatory response during coinfection. However, we recognize and suggest that robust TNFα responses are observed in a myriad of infections, and are in no way specific to influenza and SP coinfection.

There have been sporadic clinical studies simultaneously quantifying bacterial loads and cytokine levels in IAV-SP-coinfected Pna patients, and this study could thus only extrapolate bacterial loads and cytokine levels from mice to humans prudently based on an adjusted factors relating to body weight and body-surface area.[@b20-copd-12-1973] Still, this study may have failed to consider various influences on pathogenicity posed by ages, strains, and doses. More animal experimental data and clinical studies regarding IAV-SP coinfection might be helpful to minimize uncertainties and assess health risks of coinfection more adequately and accurately in future study. In addition, Lee et al indicated that ideally local (lung) cytokine production should be studied, yet lower-respiratory secretion and tissue samples are difficult to obtain.[@b30-copd-12-1973] Moreover, there are currently no standardized assay methods. Given the lungs are highly vascular, studying circulating cytokines may still provide a reasonably good approximation on their response patterns.[@b30-copd-12-1973]

Limitations and implications
----------------------------

Inflammatory cytokines could be a protective mechanism, and cytokine level could be correlated with systemic symptom dynamics. Canini and Carrat[@b31-copd-12-1973] incorporated systemic symptom dynamics and cytokine production into an influenza kinetic model such that the cytokine compartment included all cytokines, such as IL6 and IFNγ. Based on IL6- and IFNγ-induced mechanisms, including immune response and symptom development, IL6 is the acute-phase response to viral infection, and IFNγ is the important immunoresponse that could inhibit viral replication directly. IL6 and IFNγ levels from nasal wash could thus be linked to body temperature, mucus production, viral titer, and symptom scores.[@b26-copd-12-1973],[@b32-copd-12-1973] Cytokine production is related to activated macrophages or infected cells.[@b33-copd-12-1973] However, there are limited studies linking IAV-SP coinfection-induced cytokines and systemic symptom scores. Our study hence assessed cytokine responses alone as the end point of health risk.

Secondary bacterial Pna leads to increased disease severity, leading to a significant percentage of deaths during influenza pandemics.[@b34-copd-12-1973] Pneumococcal diseases and influenza have caused substantial clinical and economic burden in Taiwan, particularly in young children and people aged ≥65 years.[@b35-copd-12-1973] Moreover, the Taiwan Centers for Disease Control has incorporated severely complicated influenza and invasive pneumococcus into their list of categories III and IV notifiable communicable diseases. Continuous surveillance of respiratory illnesses and influenza antigen-detection tests are necessary to identify disease outbreaks so that infection-control measures can be promptly initiated in the inpatient and outpatient settings.

To date, the 13-valent pneumococcal conjugate vaccine (Pcv13) has been available on the private market in Taiwan to protect infants and young children against disease caused by the pneumococcus. On the other hand, Katsura et al[@b36-copd-12-1973] indicated that the hemagglutinin segment encoding the pneumococcal surface protein is a promising bivalent vaccine candidate that simultaneously confers protective immunity against both SP and influenza virus.

Under the assumptions and limitations of the variables used in the IAV-SP coinfection model, we demonstrated that 7 days' lag in bacterial coinfection resulted in the most serious susceptibility. Several studies have investigated the time course of susceptibility to SP infection after IAV infection and estimated that on average these individuals developed coinfection within 6.2 days (1.3--11.1 days) after IAV infection.[@b5-copd-12-1973],[@b9-copd-12-1973],[@b13-copd-12-1973],[@b15-copd-12-1973],[@b17-copd-12-1973] This indicates that secondary SP infection may occur concurrently with or shortly after influenza infection.[@b5-copd-12-1973] Several mechanisms have been demonstrated to affect the later stages of secondary pneumococcal infection (at 24 hours or later), rather than the initial clearance of bacterial populations.[@b11-copd-12-1973],[@b15-copd-12-1973] The increase of susceptibility to secondary pneumococcal infection due to the suppression of phagocytosis by alveolar macrophages is mainly attributed to IFNγ abundance instead of the viral burden.[@b11-copd-12-1973]

Shrestha et al[@b17-copd-12-1973] suggested that the timing of administering treatment to coinfected individuals was best within 4 days post-IAV infection to prevent enhanced susceptibility to secondary pneumococcal infection. Therefore, based on our studied results of lag timing in coinfection, we recommend that people and health care workers should be wary of secondary SP infection on day 7 postinfluenza infection for prompt and proper control-measure implementations.

In view of our findings, we conclude that SP may be a risk factor of COPD exacerbations, a sudden flare-up of COPD symptoms. A higher prevalence of bacterial colonization was found in the airway of patients with stable COPD.[@b37-copd-12-1973],[@b38-copd-12-1973] The interaction between SP and COPD can cause serious complications. Moreover, both viral and bacterial infections increase the exacerbation severity of COPD, and the patients should be hospitalized.[@b39-copd-12-1973] Viral respiratory infections, particularly those caused by influenza, increase the incidence of secondary bacterial infection, such as Pna.[@b40-copd-12-1973] There is considerable potential for significant virus--bacteria interaction in COPD.[@b40-copd-12-1973] As such, coinfection of influenza and pneumococcal strains should be acknowledged to enhance control effectiveness for influenza and pneumococcus of coinfected patients with COPD. Taken together, patients with COPD have a higher risk of getting influenza or developing Pna. People with COPD who develop Pna are highly likely to represent a mortality risk from influenza infection. Understanding the link between COPD and influenza/Pna coinfection could ensure effective and prompt treatment. Influenza and pneumococcal vaccine could reduce the risk of COPD exacerbations.[@b40-copd-12-1973]

Conclusion
==========

Our study provides an integrated risk-assessment framework for quantifying pneumococcus-exacerbation risks associated with inflammatory response based on a well-built mathematical IAV-SP coinfection dynamic model, as well as mechanistically mathematical models representing relationships between bacteria load and severity of inflammatory response. We believe that TNFα might be the most sensitive biomarker among the three explored cytokines for reflecting inflammatory response during coinfection with IAV and SP. Our research highlights that SP inoculation at day 7 post-IAV infection impacts much more on Pna-associated inflammatory responses. People and health care workers should be wary of secondary SP infection on day 7 postinfluenza infection. We hope that our quantitative risk-assessment framework can provide new insights into improvements in respiratory health, especially predominantly due to COPD.
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###### 

Relationships between bacterial loads and different cytokine levels.

**Note:** Linear regression analysis for various inflammatory cytokines (**A**) IL6, (**B**) IL10, (**C**) KC, (**D**) TNFα, and (**E**) IFNγ.

###### 

Summary of extracted data for mice coinfected with IAV and SP from previously published studies

  Age (weeks)   Species                Virus              Bacteria    Cytokines                                   Reference                                  
  ------------- ---------------------- ------------------ ----------- ------------------------------------------- -------------- --------------------------- ---------------------
  8             C57BL/6                PR8                10          Type 3 (ATCC 6303)                          10^4^          IL6, IL10, KC, TNFα, IFNγ   [@b42-copd-12-1973]
  8             C57BL/6                PR8                10          Type 3 (ATCC 6303)                          2×10^5^        IL6, IL10, KC, TNFα         [@b43-copd-12-1973]
  6--12         C57BL/6                PR8                8.6×10^2^   Type 4 (ATCC 6304)                          10^7^          IL6, IL10, TNFα, IFNγ       [@b44-copd-12-1973]
  6             BALB/c                 PR8                1.8         Type 2 (D39)                                10^2^--10^5^   IL6, IL10, KC, TNFα         [@b45-copd-12-1973]
  6--8          C57BL/6 without PAFR   PR8                10^2^       Type 2 (D39), type 3 (A66.1), type 4 (T4)   10^2^--10^4^   IL6, IL10, KC, TNFα         [@b46-copd-12-1973]
  8--10         C57BL/6                PR8                10          Type 3 (ATCC 6303)                          2×10^4^        IL10, KC, TNFα, IFNγ        [@b47-copd-12-1973]
  7--10         C57BL/6                A/FM/1/47 (H1N1)   1.4×10^5^   Type 3 (ATCC 6303)                          10^3^          KC, TNFα, IFNγ              [@b48-copd-12-1973]

**Abbreviations:** IAV, influenza A virus; SP, *Streptococcus pneumoniae*; PAFR, platelet-activating factor receptor; KC, keratinocyte chemoattractant.

###### 

Inflammatory cytokines in IAV-associated pneumonia patients

  Age (years)                                            Size   Virus     IL6 (pg/mL)                                                     TNFα (pg/mL)                                                 IFNγ (pg/mL)                                                   Reference
  ------------------------------------------------------ ------ --------- --------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------- ---------------------
  ≥17                                                    93     IAV       14.6 (6.2--40.2)[a](#tfn10-copd-12-1973){ref-type="table-fn"}   1.7 (1.2--2.3)                                               0.5 (0.5--10.8)                                                [@b49-copd-12-1973]
                                                                          14.3 (6.3--38.9)                                                1.5 (1.1--2.6)                                               0.5 (0.5--10.9)                                                
                                                                          20.4 (4.7--93.3)                                                1.8 (1.7--2.2)                                               0.5 (0.5--12.1)                                                
                                                                          12.5 (6.6--19.6)                                                1.7 (1.4--2.7)                                               18.9 (6.1--30.5)                                               
  ≥17                                                    63     H1N1pdm   45.8 (7.8--167.6)                                               0.5 (0.5--1.4)                                               0.5 (0.5--0.5)                                                 
                                                                          2.7 (1.4--4.7)                                                  0.5 (0.5--1.3)                                               0.5 (0.5--0.5)                                                 
  47 (19--66)                                            16     H1N1pdm   66.1 (102.9)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       36.3 (56.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     77.3 (153.4)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      [@b50-copd-12-1973]
  35 (13)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   42     H1N1pdm   16.4                                                                                                                         105.1                                                          [@b51-copd-12-1973]
  32 (3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}    45     H1N1pdm   210.8 (270.4)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      128.6 (157.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   32.1 (34.9)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       [@b52-copd-12-1973]
  40 (12)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   15     H1N1pdm   32.3 (37.9)[c](#tfn12-copd-12-1973){ref-type="table-fn"}        49.1 (55)[c](#tfn12-copd-12-1973){ref-type="table-fn"}       126 (138.6)[c](#tfn12-copd-12-1973){ref-type="table-fn"}       [@b53-copd-12-1973]
  45 (17)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   57     H1N1pdm   191 (507.9)[b](#tfn11-copd-12-1973){ref-type="table-fn"}        20.9 (47.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                    [@b54-copd-12-1973]
                                                                          1,074.1 (918.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}    43 (43.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                      
  31 (25--36)                                            23     IAV       64.9 (87.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                     927.7 (1,153.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   [@b55-copd-12-1973]
  31 (22--39)                                            17     H1N1pdm   47.1 (75.1)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                     754.8 (1,055.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   
  29                                                     --     H1N1pdm   245.5 (276.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                   33.2 (34.9)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       [@b56-copd-12-1973]
                                                                          101.4 (132.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}                                                                   34.2 (40.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       
  23 (11--40)                                            63     H1N1pdm   200.5 (209.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      160.8 (182.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   160 (182.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       [@b57-copd-12-1973]
                                                                          215.4 (241.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      185 (227.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     185.6 (227.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          226.6 (250.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      165.8 (193.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   165.5 (193.8)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          201.2 (218.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      219.1 (264.1)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   218.6 (264.1)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          187.5 (208.7)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      204.9 (238.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   205 (238.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       
                                                                          182.5 (212.4)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      231.5 (273.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   231.4 (273.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
  35 (11--40)                                            47     IAV       456.5 (490)[b](#tfn11-copd-12-1973){ref-type="table-fn"}        182.7 (195.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   182.8 (195.6)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          436 (513.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}        211.9 (249.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   213 (249.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}       
                                                                          478.8 (517)[b](#tfn11-copd-12-1973){ref-type="table-fn"}        203.7 (240.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   203.8 (240.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          475.3 (576.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      190.3 (202.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   190.4 (202.3)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          455.4 (516.5)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      176.6 (183.1)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   175.9 (183.1)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     
                                                                          462.9 (522.7)[b](#tfn11-copd-12-1973){ref-type="table-fn"}      193.5 (203.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}   195.9 (203.2)[b](#tfn11-copd-12-1973){ref-type="table-fn"}     

**Notes:**

Interquartile range;

standard deviation;

standard error.

**Abbreviation:** IAV, influenza A virus.

###### 

IAV and SP coinfection-associated inflammatory effect (fold) varied with cytokines, day of introducing SP post-IAV infection, and exceedance risks at 0.8, 0.5, and 0.2

  Cytokine   Exceedance risk                                                                  
  ---------- --------------------------------------------------------- ---------------------- ----------------------
             **Day 1**                                                                        
  IL6        0 (0--127)[a](#tfn14-copd-12-1973){ref-type="table-fn"}   0 (0--147)             165 (101--230)
  TNFα       48 (0--790)                                               760 (286--1,233)       1,895 (1,601--2,189)
  IFNγ       27 (0--575)                                               99 (0--494)            214 (0--526)
             **Day 7**                                                                        
  IL6        0 (0--151)                                                166 (101--231)         408 (177--639)
  TNFα       907 (483--1,331)                                          1,899 (1,604--2,194)   3,339 (2,568--4,109)
  IFNγ       114 (0--483)                                              215 (0--527)           360 (0--933)
             **Day 9**                                                                        
  IL6        0 (0--133)                                                16 (0--155)            213 (131--294)
  TNFα       261 (0--920)                                              1,006 (613--1,399)     2,176 (1,822--2,531)
  IFNγ       49 (0--547)                                               124 (0--478)           243 (0--583)

**Note:**

Median (95% CI).

**Abbreviations:** IAV, influenza A virus; SP, *Streptococcus pneumoniae*.
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![Study framework and computational algorithms used in this study.\
**Notes:** (**A**) Applied published study data. (**B**, **C**) Implemented mathematical within-host coinfection dynamic model and associated parameterization, as well as uncertainty and sensitivity analyses (refer to [Table 1](#t1-copd-12-1973){ref-type="table"} for specific symbol meanings). (**D**) Methodology and algorithm in transferring and normalizing bacterial loads, cytokine levels, and inflammatory responses. (**E**) Probabilistic risk assessment by jointing. (**F**) Implications of control-measure implements.\
**Abbreviations:** *D*~M~, bacterial load in mice; *D*~H~, bacterial load in humans; *CL*~M~, level of inflammatory cytokines in mice; *CL*~H~, level of inflammatory cytokines in humans; *K*~M~, body-surface area-related transfer factors for mice; *K*~H~, body-surface area-related transfer factors for humans; *IE*, inflammatory effect; *CL*~Pna,2.5~, the 2.5% tile of inflammatory cytokine levels estimated from patients with influenza-associated pneumonia; *P*(*D*~H~), prior probability; *P*(*IE*\|*D*~H~), conditional probability; *P*(*R*~CoI~(*IE*)), posterior probability.](copd-12-1973Fig1){#f1-copd-12-1973}

![IAV and SP coinfection dynamics within hosts.\
**Notes:** (**A**) Epithelial cells, including uninfected (*T*, brown line), unproductive infected (*I*, dashed line), and virus-productive infected (*J*, green line) cells; (**B**) pathogens consisting of IAV (*V*, blue line) and SP (*B*, pink line).\
**Abbreviations:** IAV, influenza A virus; SP, *Streptococcus pneumoniae*.](copd-12-1973Fig2){#f2-copd-12-1973}

![Cytokine-specific inflammatory effects postcoinfection in response to various human bacteria loads.\
**Notes:** (**A**) IL6; (**B**) TNFα; (**C**) IFNγ.](copd-12-1973Fig3){#f3-copd-12-1973}

![Sensitivity analysis represented with bacteria-load distributions corresponding to changes in IAV and SP coinfection-related parameters.\
**Abbreviations:** IAV, influenza A virus; SP, *Streptococcus pneumoniae*; *μ*, toxic death of infected cells; *a*, virion production/release-increase rate; *z*, nonlinearity of virion production/release; *φ*, decrease in phagocytosis rate; *K*~BV~, half-saturation constant.](copd-12-1973Fig4){#f4-copd-12-1973}

![Bacteria-load estimates.\
**Notes:** (**A**) Various initial virus titers; (**B**) various initial bacteria loads; (**C**) various initial virus titers and bacteria loads with SP inoculating at days 1, 7, and 9 post-IAV infection.\
**Abbreviations:** IAV, influenza A virus; SP, *Streptococcus pneumoniae*.](copd-12-1973Fig5){#f5-copd-12-1973}

![Human bacterial load and corresponded exceedance risk estimates due to coinfection.\
**Notes:** (**A**--**C**) Human bacteria-load distributions given coinfection beginning at days 1, 7, and 9 post-IAV infection, respectively. (**D**--**F**) Cytokine-specific exceedance risk profiles of inflammation based on coinfection. (**G**--**I**) Severity levels in coinfection-associated inflammation for IL6, TNFα, and IFNγ, respectively. (**D**--**I**) Days 1 (square), 7 (triangle), and 9 (circle) of coinfection taking place. (**G**--**I**) I, II, and III represent mild, moderate, and severe inflammatory responses, respectively, and ER 0.8, ER 0.5, and ER 0.2 indicate whether it is, respectively, more likely, likely, or less likely for inflammatory response to exceed a certain severity level.\
**Abbreviation:** ER, exceedance risk.](copd-12-1973Fig6){#f6-copd-12-1973}

###### 

Descriptions of governing equations used for influenza A virus and *Streptococcus pneumoniae* coinfection dynamic model[@b15-copd-12-1973]

  Description                                      Equation                                                                                     
  ------------------------------------------------ -------------------------------------------------------------------------------------------- ------
  **Influenza A virus**                                                                                                                         
  Uninfected epithelial cells (*T*)                $\frac{dT}{dt} = - \beta TV$                                                                 (T1)
  Unproductive infected cells (*I*)                $\frac{dI}{dt} = - \beta TV - kI$                                                            (T2)
  Productive infected cells (*J*)                  $\frac{dJ}{dt} = kI - \delta J$                                                              (T3)
  Influenza (*V*)                                  $\frac{dV}{dt} = pJ - cV$                                                                    (T4)
  **Influenza A virus postcoinfection**                                                                                                         
  Unproductive infected cells (*I*)                $\frac{dI}{dt} = \beta TV - kI - \mu IB$                                                     (T5)
  Productive infected cells (*J*)                  $\frac{dJ}{dt} = kI - \delta J - \mu JB$                                                     (T6)
  Influenza (*V*)                                  $\frac{dV}{dt} = pJ\left( {I + \alpha B^{Z}} \right) - cV$                                   (T7)
  ***Streptococcus pneumoniae* postcoinfection**                                                                                                
  *S. pneumoniae* (*B*)                            $\begin{matrix}                                                                              (T8)
                                                   {\frac{dB}{dt} = rB\left( {I - \frac{B}{K_{B}\left( {I + \psi V_{C}} \right)}} \right)} \\   
                                                   {\quad - \gamma M_{A}FM_{A}^{*}B\left( {I - \frac{\phi V_{C}}{K_{BV} + V_{C}}} \right)} \\   
                                                   \end{matrix}$                                                                                
  Phagocytosis-decreasing function (*F*)           $F = f\left( {B,M_{A}} \right) = \frac{n^{2}M_{A}}{B^{2} + n^{2}M_{A}}$                      (T9)

**Abbreviations:** *β*, virus infectivity; *k*, transition rate of infected cells in eclipse phase; *δ*, infected cell-death rate; *p*, virus-production rate; *c*, virus-clearance rate; *r*, bacteria-growth rate; *K*~B~, carrying capacity; *M*~A~\*, steady-state macrophages; *γM*~A~, phagocytosis rate; *n*, maximum bacteria (phagocytosis) per *M*~A~; coinfection-associated param eters; *μ*, toxic death of infected cells; *a*, virion production/release-increase rate; *z*, nonlinearity of virion production/release; *ψ*, increase in carrying capacity; *ϕ*, decrease in phagocytosis rate; *K*~BV~, half-saturation constant.

###### 

Parameter values used in influenza A virus and *Streptococcus pneumoniae* coinfection model

  Parameter                        Description                                          Unit                        Value
  -------------------------------- ---------------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------
  **Influenza A virus**                                                                                             
  *β*                              Virus infectivity                                    1/(TCID~50~⋅mL^−1^ × day)   2.8×10^−6^
  *k*                              Transition rate of infected cells in eclipse phase   Day^−1^                     4
  *δ*                              Infected cell-death rate                             Day^−1^                     0.89
  *p*                              Virus-production rate                                1/(TCID~50~⋅mL^−1^ × day)   25.1
  *c*                              Virus-clearance rate                                 Day^−1^                     28.4
  *T*(0)                           Initial uninfected cells                             Cells                       10^7^
  *I*(0)                           Initial unproductive infected cells                  Cells                       0
  *J*(0)                           Initial productive infected cells                    Cells                       0
  *V*(0)                           Initial virus titer                                  TCID~50~⋅mL^−1^             1 (0.35--2.96)[a](#tfn3-copd-12-1973){ref-type="table-fn"},[b](#tfn4-copd-12-1973){ref-type="table-fn"}
  ***Streptococcus pneumoniae***                                                                                    
  *r*                              Bacteria-growth rate                                 Day^−1^                     27
  *K*~B~                           Carrying capacity                                    CFU⋅m L^−1^                 2.3×10^8^
  *M*~A~^\*^                       Steady-state macrophages                             Cells                       10^6^
  *γM*~A~                          Phagocytosis rate                                    Cells^−1^ day^−1^           1.35×10^−4^
  *n*                              Maximum bacteria per MA                              CFU⋅m L^−1^ cell^−1^        5
  *B*(0)                           Initial bacteria load                                CFU⋅m L^−1^                 10^2^--10^5^,[c](#tfn5-copd-12-1973){ref-type="table-fn"}
  **Coinfection**                                                                                                   
  *ψ*                              Increase in carrying capacity                        1/TCID~50~⋅mL^−1^           1.2×10^−8^
  *ϕ*                              Decrease in phagocytosis rate                        --                          0.87 (0.86--0.91)
  *K*~BV~                          Half-saturation constant                             TCID~50~⋅mL^−1^             1.8×10^3^ (5.7×10^2^--9.4×10^3^)
  *μ*                              Toxic death of infected cells                        1/CFU⋅ mL^−1^               5.2×10^−10^ (0--0.43)
  *a*                              Increase in virion production/release                (CFU⋅m L^−1^)^−^*^z^*       1.2×10^−3^ (1.4×10^−4^--4.3×10^−1^)
  *z*                              Nonlinearity of virion production/release            --                          0.5 (0.14--0.61)

**Notes:** Values derived from Smith et al[@b15-copd-12-1973] unless otherwise noted.

Estimated from Chen et al;[@b41-copd-12-1973]

median (95% CI);

estimated from Smith et al[@b15-copd-12-1973] and Shrestha et al.[@b17-copd-12-1973]

**Abbreviations:** *β*, virus infectivity; *k*, transition rate of infected cells in eclipse phase; *δ*, infected cell-death rate; *p*, virus-production rate; *c*, virus-clearance rate; *r*, bacteria-growth rate; *K*~B~, carrying capacity; *M*~A~\*, steady-state macrophages; γ*M*~A~, phagocytosis rate; *n*, maximum bacteria (phagocytosis) per *M*~A~; coinfection-associated parameters; *μ*, toxic death of infected cells; *a*, virion production/release-increase rate; *z*, nonlinearity of virion production/release; *ψ*, increase in carrying capacity;*ϕ*, decrease in phagocytosis rate; *K*~BV~, half-saturation constant.

###### 

Conversion of bacteria load and cytokine level between mice and humans and normalized inflammatory effect

  Bacteria load   Cytokine level   Normalized inflammatory effect for humans (fold)[b](#tfn8-copd-12-1973){ref-type="table-fn"}          
  --------------- ---------------- ---------------------------------------------------------------------------------------------- ------ -------
  **IL6**                                                                                                                                
  7.89            6.84             4.21                                                                                           3.16   256
  8.5             7.45             4.27                                                                                           3.22   294
  5.46            4.41             3.41                                                                                           2.36   39
  7.2             6.15             3.9                                                                                            2.85   124
  6.75            5.7              3.91                                                                                           2.86   128
  6.74            5.69             3.9                                                                                            2.85   123
  7.67            6.62             3.92                                                                                           2.87   129
  **TNFα**                                                                                                                               
  7.89            6.84             4.05                                                                                           3      2,419
  7.94            6.89             4.06                                                                                           3.01   2,506
  5.46            4.41             3.68                                                                                           2.63   1,035
  7.2             6.15             3.92                                                                                           2.87   1,790
  6.75            5.7              3.93                                                                                           2.88   1,832
  6.74            5.69             3.87                                                                                           2.82   1,605
  7.87            6.82             3.93                                                                                           2.88   1,850
  7.67            6.62             3.91                                                                                           2.86   1,766
  3.61            2.56             2.75                                                                                           1.7    122
  **IFNγ**                                                                                                                               
  8.5             7.45             2.93                                                                                           1.88   329
  3.61            2.56             2.03                                                                                           0.98   41
  8.16            7.11             2.71                                                                                           1.66   196

**Notes:**

Adjusted by using human equivalent dose -- (*D*~H~, *CL*~H~) = (*D*~M~, *CL*~M~)× *K*~M~ *K*~H~[@b20-copd-12-1973], where *D*~H~, *D*~M~, *CL*~H~, and *CL*~M~ represent bacteria load (*D*) or cytokine level (*CL*) for humans and mice ([Table S1](#SD2-copd-12-1973){ref-type="supplementary-material"}), respectively, and *K*~M~ and *K*~H~ are the body surface area-related transfer factors for mice and human, respectively, of 3 and 37 kg m^−2^;

normalized coinfection-induced inflammatory effects (*IE*) -- *IE* = (*CL*~H~ − *CL*~Pna,2.5~) *CL*~Pna,2.5~, where *CL*~H~ is the level of inflammatory cytokines in humans and *CL*~Pna,2.5~ represents the 2.5% tile of inflammatory cytokine levels estimated from patients with influenza-associated pneumonia ([Table S2](#SD3-copd-12-1973){ref-type="supplementary-material"}).
